journal
Journals American Journal of Clinical O...

American Journal of Clinical Oncology

https://read.qxmd.com/read/38148710/survival-benefit-of-primary-tumor-resection-combined-with-chemotherapy-in-patients-with-unresectable-colorectal-mucinous-adenocarcinoma-with-liver-metastasis
#21
JOURNAL ARTICLE
Shu-Wen Liao, Jie-Qun Zhan, Chu-Tian Liu, Hai-Tao Yu, Min-Jie Wen
OBJECTIVE: To evaluate the survival benefit of combining primary tumor resection (PTR) and chemotherapy in patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM). METHODS: We obtained data from the surveillance, epidemiology, and end results database for patients with UCR-MAC-LM from 2010 to 2017. Clinicopathological characteristics were analyzed using the χ2 test. Propensity score matching was performed to balance baseline characteristics...
January 1, 2024: American Journal of Clinical Oncology
https://read.qxmd.com/read/37823720/treatment-of-recurrent-low-grade-serous-ovarian-cancer-with-mek-inhibitors-a-systematic-review
#22
JOURNAL ARTICLE
Anjali Kulkarni, Carly Cooke, Rouhi Fazelzad, Michael Fung-Kee-Fung, Taymaa May, Tiffany Zigras
OBJECTIVE: Low-grade serous ovarian cancer (LGSC) represents 5% of all epithelial ovarian cancers. They are characterized by indolent growth and KRAS and BRAF mutations, differing from high-grade serous ovarian cancer both clinically and molecularly. LGSC has low response rates to traditional systemic therapies, including chemotherapy and hormonal therapy. The objective of this systematic review was to appraise the literature describing the efficacy of MEK inhibitors in the treatment of LGSC...
January 1, 2024: American Journal of Clinical Oncology
https://read.qxmd.com/read/38153244/acr-ars-practice-parameter-for-radiation-oncology
#23
JOURNAL ARTICLE
Simon Lo, Samuel Chao, Eleanor Harris, Jonathan Knisely, Join Y Luh, Pranshu Mohindra, Tony S Quang, Jason Ye, William Small, Naomi R Schechter
AIM/OBJECTIVES/BACKGROUND: This practice parameter was revised collaboratively by the American College of Radiology (ACR), and the American Radium Society. This practice parameter provides updated reference literature regarding radiation oncology practice and its key personnel. METHODS: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www...
December 28, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38149838/acr-ars-practice-parameter-for-communication-radiation-oncology
#24
JOURNAL ARTICLE
Hina Saeed, Paul Wallner, James Bates, Anupama Chundury, Laura Freedman, Timur Mitin, Gary Walker, William Small, Naomi R Schechter
AIM/OBJECTIVES/BACKGROUND: This practice parameter was revised collaboratively by the American College of Radiology (ACR), and the American Radium Society (ARS). Timely, accurate, and effective communications are critical to quality and safety in contemporary medical practices. Radiation oncology incorporates the science and technology of complex, integrated treatment delivery and the art of providing care to individual patients. Through written physical and/or electronic reports and direct communication, radiation oncologists convey their knowledge and evaluation regarding patient care, clinical workup, and treatment provided to others in the management of the patient...
December 25, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38148589/impact-of-maximum-point-dose-within-the-planning-target-volume-on-local-control-of-nonsmall-cell-lung-cancer-treated-with-stereotactic-body-radiotherapy
#25
JOURNAL ARTICLE
Erica L Braschi, Christopher G Morris, Anamaria R Yeung, Alexandra N De Leo
OBJECTIVE: No consensus exists on the maximum dose delivered to the planning target volume (PTV) in the delivery of stereotactic body radiotherapy (SBRT) for primary lung cancer. We investigated whether higher biologically effective doses (BED) within the PTV were associated with improved tumor control. METHODS: We reviewed patients with early-stage, node-negative nonsmall cell lung cancer who received curative-intent SBRT between 2005 and 2018. We calculated the maximum BED (maxBED) within the PTV for all patients, analyzing outcomes using the cumulative incidence method and Fine-Gray test statistics to assess prognostic impact...
December 25, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38131628/executive-summary-of-the-american-radium-society-appropriate-use-criteria-for-neoadjuvant-therapy-for-nonmetastatic-pancreatic-adenocarcinoma-systematic-review-and-guidelines
#26
JOURNAL ARTICLE
Krishan R Jethwa, Ed Kim, Jordan Berlin, Christopher J Anker, Leila Tchelebi, Gerard Abood, Christopher L Hallemeier, Salma Jabbour, Timothy Kennedy, Rachit Kumar, Percy Lee, Navesh Sharma, William Small, Vonetta Williams, Suzanne Russo
For patients with locoregionally confined pancreatic ductal adenocarcinoma (PDAC), margin-negative surgical resection is the only known curative treatment; however, the majority of patients are not operable candidates at initial diagnosis. Among patients with resectable disease who undergo surgery alone, the 5-year survival remains poor. Adjuvant therapies, including systemic therapy or chemoradiation, are utilized as they improve locoregional control and overall survival. There has been increasing interest in the use of neoadjuvant therapy to obtain early control of occult metastatic disease, allow local tumor response to facilitate margin-negative resection, and provide a test of time and biology to assist with the selection of candidates most likely to benefit from radical surgical resection...
December 22, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38131531/validation-of-cts5-model-in-large-scale-breast-cancer-population-and-combination-of-cts5-and-ki-67-status-to-develop-a-novel-nomogram-for-prognosis-prediction
#27
JOURNAL ARTICLE
Lizhi Ning, Yaobang Liu, Xuefang He, Rui Han, Yuanfang Xin, Jiuda Zhao, Xinlan Liu
BACKGROUND: More than half of patients with early-stage estrogen receptor-positive (ER+) breast cancer relapse after completing 5 years of adjuvant endocrine therapy, so it is important to determine which patients are candidates for extended endocrine therapy. The clinical treatment score after 5 years (CTS5) is a prognostic tool developed based on postmenopausal ER+ breast cancer to assess the risk of late distant recurrence (LDR) after 5 years of adjuvant endocrine therapy for breast cancer...
December 22, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38131352/acr-acnm-ars-astro-snmmi-practice-parameter-for-the-performance-of-therapy-with-radiopharmaceuticals
#28
JOURNAL ARTICLE
Paul E Wallner, Don C Yoo, Jeremy Calais, Freddy E Escorcia, Carina Mari Aparici, Jeff Michalski, Michael Morris, Zachary S Morris, Daniel Pryma, Bryan M Rabatic, Navesh Sharma, Neha Vapiwala, Munir V Ghesani, Rathan M Subramaniam, William Small, Naomi R Schechter
OBJECTIVES: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine, the American Radium Society, the American Society for Radiation Oncology, and the Society of Nuclear Medicine and Molecular Imaging. The document is intended to serve as a resource for appropriately trained and licensed physicians who perform therapeutic procedures with unsealed sources, referred to in the document using the more inclusive terminology of radiopharmaceuticals, for which a written directive is required for authorized users under NRC 10 CFR 35...
December 22, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38145412/emerging-futuristic-targeted-therapeutics-a-comprising-study-towards-a-new-era-for-the-management-of-tnbc
#29
JOURNAL ARTICLE
Tanuma Mistry, Arijit Nath, Ranita Pal, Sushmita Ghosh, Sutapa Mahata, Pranab Kumar Sahoo, Sinjini Sarkar, Trisha Choudhury, Partha Nath, Neyaz Alam, Vilas D Nasare
Triple-negative breast cancer is characterized by high lethality attributed to factors such as chemoresistance, transcriptomic, and genomic heterogeneity, leading to a poor prognosis and limiting available targeted treatment options. While the identification of molecular targets remains pivotal for therapy involving chemo drugs, the current challenge lies in the poor response rates, low survival rates, and frequent relapses. Despite various clinical investigations exploring molecular targeted therapies in conjunction with conventional chemo treatment, the outcomes have been less than optimal...
December 19, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38088232/long-term-outcomes-after-abdominal-radiation-for-wilms-tumor-a-20-year-experience
#30
JOURNAL ARTICLE
Brianna Conte, Colette Shen, Patrick Thompson, Ian Davis, Dana L Casey
BACKGROUND: As radiation therapy (RT) for Wilms tumor (WT) evolves with more conformal techniques, it is necessary to evaluate patterns of failure and toxicity. We sought to determine the rate of local failure (LF) after abdominal RT in WT, specifically focusing on those with contained rupture treated with whole abdominal and pelvic RT (WAPRT) vs flank RT. Secondary objectives were to determine overall survival (OS), distant failure (DF), and late toxicities. METHODS: A single institution retrospective study of 54 pediatric patients with WT treated with abdominal RT between May 2000 and October 2022...
December 13, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38054473/diagnosis-of-malignant-pulmonary-nodules-using-a-combination-of-tumor-associated-autoantibodies-and-computed-tomography
#31
JOURNAL ARTICLE
Xiao Liu, Qing Shen, Yuchan Wen, Zhijiao Jiang, Zheng Ma, Pinqiang Zeng, Jian He, Yu Liao, Yong Huang, Jing Huang
BACKGROUND: Diagnosis of malignant pulmonary nodules can greatly reduce the occurrence of lung cancer death, and computed tomography (CT) is commonly used in diagnosis. In addition, tumor-associated autoantibodies (TAAbs) show high specificity and stability. We aim to establish a computable risk model of pulmonary nodules by combining CT with TAAb detection. METHODS: The concentrations of 7 TAAbs (p53, PGP9.5, SOX2, GAGE7, GBU4-5, CAGE, MAGEA1, and CAGE) were assayed using the enzyme-linked immunosorbent assay in 136 patients with pulmonary nodules (84 with newly diagnosed lung adenocarcinoma, 21 with squamous cell carcinoma, and 31 with benign nodules) and 42 control subjects without pulmonary nodules...
December 4, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38047455/long-term-survival-among-patients-with-de-novo-human-epidermal-growth-receptor-2-positive-metastatic-breast-cancer-in-manitoba
#32
JOURNAL ARTICLE
Erin N McAndrew, Jeffrey Graham, Brenden Dufault, Danielle N Desautels, Christina A Kim
OBJECTIVES: Although metastatic breast cancer (MBC) is considered incurable, human epidermal growth receptor 2 (HER2)-directed therapy has improved outcomes significantly, with some patients experiencing durable responses to treatment. The aim of this study was to identify potential predictors of long-term survival (LTS) among patients with de novo HER2-positive MBC who received HER2-directed treatment. METHODS: Eligible patients from 2008 to 2018 were identified using the Manitoba Cancer Registry...
December 4, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38047447/predictors-of-survival-in-patients-with-hepatocellular-cancer-receiving-atezolizumab-and-bevacizumab
#33
JOURNAL ARTICLE
Matthew Ledenko, Lydia Mercado, Tushar Patel
OBJECTIVES: In randomized clinical trials in patients with hepatocellular cancer (HCC), combination therapy with atezolizumab and bevacizumab (Atezo-Bev) prolonged survival, and these treatments have become the standard first-line therapy for advanced HCC. However, clinical trials may not reflect real-life clinical practice due to treatment selection criteria. Thus, our aim was to understand predictors of HCC outcomes with these treatments in a real-world, multicenter setting. METHODS: A retrospective review of all patients 18 years of age or older treated for advanced primary liver cancer between February 2020 and August 2022 was conducted to assess the relationship between overall survival and clinical and biochemical variables before or during treatment...
December 4, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/37986208/genomic-and-molecular-characteristics-of-ovarian-carcinosarcoma
#34
REVIEW
Kristy Ramphal, Matthew J Hadfield, Christina M Bandera, Jesse Hart, Don S Dizon
Ovarian carcinosarcoma (OCS) is a rare malignancy with a poor prognosis. It is a biphasic tumor with malignant epithelial and mesenchymal components. A few mutations commonly seen in cancer have been identified in OCS, including TP53, PIK3CA, c-myc, ZNF217, ARID1A, and CTNNB1. Some OCS tumors have shown vascular endothelial growth factor positivity and limited HER2 expression. There is evidence of homologous recombination deficiency in OCS. This malignancy can be categorized as copy number high but has not been shown to have a high tumor mutational burden...
December 1, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/37779240/a-meta-analysis-of-randomised-controlled-trials-comparing-combination-therapy-as-second-line-treatment-with-monotherapy-in-advanced-non-small-cell-lung-cancer-with-epidermal-growth-factor-receptor-mutation
#35
JOURNAL ARTICLE
Kai-Xiang Zhao, Yan-Fang Zhang, Lei Zheng, Ya-Fei Pan, Ze-Huang He
BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are standard therapy for patients with non-small cell lung cancer (NSCLC) with EGFR mutation; however, resistance is common. Combinatorial strategies have been explored to improve survival. This meta-analysis assesses the efficacy and safety of combination therapy versus monotherapy in patients with advanced NSCLC who failed first-line EGFR-tyrosine kinase inhibitor treatment. METHODS: We searched randomized controlled trials from PubMed, Web of Science, Google Scholar, Cochrane Library, and ClinicalTrial...
December 1, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38054725/pretreatment-characteristics-of-carcinoid-tumors-of-the-lung-which-predict-aggressive-behavior-erratum
#36
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 29, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38018533/creatine-supplementation-and-resistance-training-in-patients-with-breast-cancer-cartic-study-protocol-for-a-randomized-controlled-trial
#37
JOURNAL ARTICLE
Aitor Martinez Aguirre-Betolaza, Jon Cacicedo, Arkaitz CastaƱeda-Babarro
BACKGROUND/AIMS: Creatine supplementation is an effective ergogenic nutrient for athletes, as well as for people starting a health or fitness program. Resistance training has previously been identified as an important method of increasing muscle mass and strength, especially in people with cancer to avoid sarcopenia. The potential of creatine supplementation for adaptations produced by resistance training in patients with cancer is still unknown. The primary aim of this study is to evaluate the effectiveness of a supervised resistance training program intervention with and without creatine supplementation in patients with breast cancer...
November 29, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/38011024/impact-of-pretreatment-weight-loss-on-radiotherapy-utilization-and-clinical-outcomes-in-non-small-cell-lung-cancer
#38
JOURNAL ARTICLE
Christian M Alvarez, Maureen Aliru, Bhavani S Gannavarapu, Tidie Song, Linda Anne Gilmore, Santiago Olaechea, Daniel R Gomez, Chul Ahn, Rodney E Infante, Puneeth Iyengar
BACKGROUND: Cancer cachexia is a syndrome of unintentional weight loss resulting in progressive functional impairment. Knowledge of radiation therapy utilization in patients with cancer cachexia is limited. We evaluated the use of curative and palliative-intent radiation for the management of patients with non-small cell lung cancer (NSCLC) with cachexia to determine whether tumor-directed therapy affected cachexia-associated outcomes. METHODS: Using an Institutional Tumor Registry, we evaluated all patients with stages of NSCLC treated at a tertiary care system from 2006 to 2013...
November 24, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/37981697/sbrt-vs-y90-hcc-treatment-outcomes-and-costs
#39
JOURNAL ARTICLE
Mark F deBettencourt, Yirong Liu, Scott J Cotler, Chris A Molvar, Tamer Abdelrahman, Tarita O Thomas
OBJECTIVES: Stereotactic Body Radiotherapy (SBRT) and Yttrium-90 (Y90) are among the ablative therapies used as treatment options for localized hepatocellular carcinoma (HCC). To date, direct comparisons of the 2 modalities' outcomes and costs are lacking. This study aimed to analyze demographic, treatment, and cost information for patients with HCC treated with SBRT and Y90. METHODS: Patients with HCC treated with SBRT or Y90 radioembolization between January 2018 and January 2020 at one institution were retrospectively reviewed...
November 20, 2023: American Journal of Clinical Oncology
https://read.qxmd.com/read/37749786/neoadjuvant-immunotherapy-and-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#40
JOURNAL ARTICLE
Shaofu Yu, Shasha Zhai, Qian Gong, Chunhong Xiang, Jianping Gong, Lin Wu, Xingxiang Pu
OBJECTIVES: To systematically evaluate the effectiveness and safety of neoadjuvant immunotherapy for patients with non-small cell lung cancer (NSCLC). METHODS: Randomized controlled trials of neoadjuvant immunotherapy in treating patients with NSCLC were comprehensively retrieved from electronic databases, eligible studies, previous systematic reviews and meta-analyses, guidelines, and conference abstracts. The meta-analysis was performed by the Stata/SE 12.0 software...
November 1, 2023: American Journal of Clinical Oncology
journal
journal
28347
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.